Recent Updates
Recently added Catalysts
VKTX Positive Sentiment

Geoffrey Barker, Ph.D.

Key Takeaway: Geoffrey Barker, Ph.D., has been appointed as Chief Development Officer at Viking Therapeutics. With 30 years of experience in pharmaceutical and nonclinical development, he previously held senior roles at various companies, including overseeing Phase 1 and Phase 2 candidates. Dr. Barker holds a Ph.D. in analytical chemistry from the State University of New York at Binghamton.
Price reaction · baseline $38.55 (2025-12-05 close) · 4 other VKTX headline(s) in the window, move may be shared
day 0 close · peak
-1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Barker has extensive experience in pharmaceutical development.
  • He has a strong background in overseeing clinical candidates.
  • His leadership roles indicate a high level of expertise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

Geoffrey Barker, Ph.D. serves as our Chief Development Officer. Dr. Barker has 30 years of pharmaceutical and nonclinical development experience. Before being appointed as Chief Development Officer, Dr. Barker served as Senior Vice President of Pharmaceutical Development at Viking Therapeutics. Prior to joining Viking, he was Project Director at Pyramid Laboratories, a fill/finish aseptic manufacturing facility. Before joining Pyramid, Dr. Barker was senior director of Product Development at Aires Pharmaceuticals, Inc., a company focused on developing therapies for pulmonary vascular disorders. Dr. Barker has also previously served as associate director of pharmaceutical development at TargeGen, Inc., where he oversaw the development of two Phase 2 candidates and one Phase 1 candidate for the treatment of hematological malignancies and certain other disorders and as a scientist at Merck and Company (previously SIBIA Neurosciences), a biotech company focused on central nervous system disorders. Dr. Barker earned a Ph.D. in analytical chemistry from the State University of New York at Binghamton.

Frequently Asked Questions

What is Dr. Geoffrey Barker's role at Viking Therapeutics?

Dr. Geoffrey Barker serves as the Chief Development Officer at Viking Therapeutics.

How many years of experience does Dr. Barker have?

Dr. Barker has 30 years of experience in pharmaceutical and nonclinical development.

Where did Dr. Barker work before Viking Therapeutics?

Before joining Viking, he was Senior Vice President of Pharmaceutical Development.

What degree does Dr. Barker hold?

Dr. Barker earned a Ph.D. in analytical chemistry from the State University of New York.

Last updated: Dec 7, 2025